Memantine augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial

Journal of Clinical Psychopharmacology

Volumn 29, Issue 1, 2009, Pages 51-55

  Aboujaoude, Elias ^a   Barry, John J ^a   Gamel, Nona ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; GABAPENTIN; LORAZEPAM; MEMANTINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; AMINO ACID RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; DIZZINESS; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; MALE; NAUSEA; NIGHT SWEAT; OBSESSIVE COMPULSIVE DISORDER; OPEN STUDY; PRIORITY JOURNAL; RATING SCALE; SOMNOLENCE; SYMPTOM; YALE BROWN OBSESSIVE COMPULSIVE SCALE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG RESISTANCE; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ADULT; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; MALE; MEMANTINE; OBSESSIVE-COMPULSIVE DISORDER; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 62649108518     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318192e9a4     Document Type: Article

References (34)

1. Koran LM, Hanna GL, Hollander E, et al. Practice Guidelines for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. 2007;164(suppl 7):5-53.
2. Murray CJ, Lopez AD. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Cambridge, MA: Harvard University Press; 1996.
3. Coric V, Taskiran S, Pittenger C, et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry. 2005;58:424-428.
4. Koran LM. Obsessive-Compulsive and Related Disorders in Adults: A Comprehensive Clinical Guide. Cambridge, UK: Cambridge University Press; 1999.
5. Fineberg NA, Gale TM. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2005;8:107-129.
6. Zohar J. Escitalopram in the treatment of obsessive-compulsive disorder. Expert Rev Neurother. 2008;8:339-349.
7. Dell'Osso B, Nestadt G, Allen A, et al. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review. J Clin Psychiatry. 2006;67:600-610.
8. Dell'osso B, Mundo E, Marazziti D, et al. Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series. J Psychopharmacol. 2008;22:210-213.
9. Greenberg BD, Price LH, Rauch SL, et al. Neurosurgery for intractable obsessive-compulsive disorder and depression: critical issues. Neurosurg Clin N Am. 2003;14:199-212.
10. Rosenberg DR, MacMaster FP, Keshavan MS, et al. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry. 2000;39:1096-1103.
11. Bolton J, Moore GJ, MacMillan S, et al. Case study: caudate glutamatergic changes with paroxetine persist after medication discontinuation in pediatric OCD. J Am Acad Child Adolesc Psychiatry. 2001;40:903-906.
12. Moore GJ, MacMaster FP, Stewart C, et al. Case study: caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 1998;37:663-667.
13. Carlsson ML. On the role of cortical glutamate in obsessive-compulsive disorder and attention-deficit hyperactivity disorder, two phenomenologically antithetical conditions. Acta Psychiatr Scand. 2000;102:401-413.
14. Rosenberg DR, MacMillan SN, Moore GJ. Brain anatomy and chemistry may predict treatment response in paediatric obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2001;4:179-190.
15. Chakrabarty K, Bhattacharyya S, Christopher R, et al. Glutamatergic dysfunction in OCD. Neuropsychopharmacology. 2005;30: 1735-1740.
16. Arnold PD, Rosenberg DR, Mundo E, et al. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology (Berl). 2004;174:530-538.
17. Delorme R, Krebs MO, Chabane N, et al. Frequency and transmission of glutamate receptors GRIK2 and GRIK3 polymorphisms in patients with obsessive compulsive disorder. Neuroreport. 2004;15:699-702.
18. Arnold PD, Sicard T, Burroughs E, et al. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry. 2006;63:769-776.
19. Dickel DE, Veenstra-VanderWeele J, Cox NJ, et al. Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Arch Gen Psychiatry. 2006;63:778-785.
20. Nordstrom EJ, Burton FH. A transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder circuitry. Mol Psychiatry. 2002;7:617-625.
21. McGrath MJ, Campbell KM, Parks CR, et al. Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder. Brain Res. 2000;877:23-30.
22. Egashira N, Okuno R, Harada S, et al. Effects of glutamate-related drugs on marble-burying behavior in mice: Implications for obsessive-compulsive disorder. Eur J Pharmacol. 2008. 2008;586:164-170.
23. Ichimaru Y, Egawa T, Sawa A. 5-HT1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice. Jpn J Pharmacol. 1995;68:65-70.
24. Shinomiya K, Fujii Y, Sugimoto Y, et al. Effect of paroxetine on marble-burying behavior in mice. Methods Find Exp Clin Pharmacol. 2005;27:685-687.
25. Lafleur DL, Pittenger C, Kelmendi B, et al. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology. 2006;184:254-256.
26. Grant P, Lougee L, Hirschtritt M, et al. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2007;17:761-767.
27. Lipton SA. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res. 2005;2:155-165.
28. Chipana C, Camarasa J, Pubill D, et al. Memantine prevents MDMA-induced neurotoxicity. Neurotoxicology. 2008;29:179-183.
29. Poyurovsky M, Weizman R, Weizman A, et al. Memantine for treatment-resistant OCD. Am J Psychiatry. 2005;162:2191-2192.
30. Pasquini M, Biondi M. Memantine augmentation for refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:1173-1175.
31. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33.
32. Goodman WK, Price H, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, 1: development, use, and reliability. Arch Gen Psychiatry. 1989;46:1006-1011.
33. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976.
34. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.